Galapagos achieves milestones in osteoporosis alliance
In 2008, Lilly and Galapagos initiated their alliance to develop new medicines for the treatment of osteoporosis. The alliance agreement provides Lilly access to 12 of Galapagos' novel target based programs in osteoporosis, with Galapagos responsible for the development of drug candidates through to Phase IIa clinical Proof of Concept. To date, Galapagos has received a total of €9.8 million in payments from Lilly under the alliance.
"Our drug discovery approach has shown substantial progress despite the challenges intrinsic to working in the osteoporosis field," said Onno van de Stolpe, Galapagos' CEO. "The lead molecules that we have identified thus far show bone-building properties and we are further optimizing these molecules to deliver orally-available small molecules to Lilly's development team."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.